Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: A randomized study

Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: A randomized study

Highlights • GS-4774 is being developed as a therapeutic vaccine for chronic HBV infection. • GS-4774 consists of yeast cells that express well-conserved regions of HBV proteins. • GS-4774 was safe and well-tolerated in healthy subjects at all doses evaluated. • GS-4774 led to HBV-specific immune re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2014-09, Vol.32 (39), p.4925-4931
Hauptverfasser: Gaggar, Anuj, Coeshott, Claire, Apelian, David, Rodell, Timothy, Armstrong, Brian R, Shen, Gong, Subramanian, G. Mani, McHutchison, John G
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
Allergy and Immunology
Amino acids
Applied microbiology
Biological and medical sciences
Drug therapy
Female
Fundamental and applied biological sciences. Psychology
GS-4774
HBV
Healthy subjects
Healthy Volunteers
Hepatitis
Hepatitis B Antibodies - blood
Hepatitis B Vaccines - adverse effects
Hepatitis B Vaccines - immunology
Hepatitis B Vaccines - therapeutic use
Hepatitis B virus
Hepatitis B, Chronic - therapy
Humans
Immunity, Cellular
Immunization
Immunization, Secondary
Immunogenicity
Immunotherapy
Infections
Injection
Interferon-gamma - immunology
Laboratories
Lymphocytes
Male
Microbiology
Middle Aged
Miscellaneous
Peptides
Saccharomyces cerevisiae
T-Lymphocytes - immunology
Vaccine
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Vaccines, Synthetic - adverse effects
Vaccines, Synthetic - immunology
Vaccines, Synthetic - therapeutic use
Virology
Yeast
Yeasts
Young Adult
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Highlights • GS-4774 is being developed as a therapeutic vaccine for chronic HBV infection. • GS-4774 consists of yeast cells that express well-conserved regions of HBV proteins. • GS-4774 was safe and well-tolerated in healthy subjects at all doses evaluated. • GS-4774 led to HBV-specific immune responses after weekly and monthly immunization. • GS-4774 is being tested in patients with chronic HBV infection.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2014.07.027